Research and Markets has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2016" report to their offering.
Hypersensitivity pipeline therapeutics constitutes close to 138 molecules. Out of which approximately 122 molecules are developed by Companies and remaining by the Universities
Institutes. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 7, 15, 13, 56, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 2 molecules, respectively.
Hypersensitivity - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/7qjh39/hypersensitivity
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006189/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.